Clinical trials: Migraine With Aura
Migraine, Patent Foramen Ovale
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
- Conditions
- Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
- Trial name
- RELIEF (NCT04100135)
- Testing
- Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel)
- Where
- 15 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- W.L.Gore & Associates
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Acute Migraine With or Without Aura in Adolescents
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17…
- Trial name
- NCT01004263
- Testing
- rizatriptan benzoate
- Volunteers
- 674 people
- Sponsor
- Organon and Co
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline
Migraine Without Aura, Migraine With Aura
Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT03361423
- Testing
- Nerivio Migra-1 active device
- Where
- 12 sites in United States, Israel
- Volunteers
- 296 people
- Sponsor
- Theranica
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines.
- Trial name
- NCT00122278
- Testing
- Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 205 people
- Sponsor
- Montefiore Medical Center
Acute Migraine With or Without Aura
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
- Trial name
- NCT03338920
- Testing
- sumatriptan nasal powder
- Where
- 40 sites in United States
- Volunteers
- 159 people
- Sponsor
- Currax Pharmaceuticals
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine, Headaches
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
This study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN DEVICE can reduce the pain associated with migraine headaches in 30 minutes after use.
- Trial name
- COMPASS (NCT01667679)
- Where
- 13 sites in United States
- Volunteers
- 275 people
- Sponsor
- Avanir Pharmaceuticals
Migraine With Aura
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the…
- Trial name
- NCT00449540
- Testing
- Active Transcranial Magnetic Stimulation (TMS) Device
- Where
- 14 sites in United States
- Volunteers
- 201 people
- Sponsor
- Neuralieve
Migraine
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine.
- Trial name
- NCT00442936
- Testing
- Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Headache, With or Without Aura
Staccato Prochlorperazine in Migraine (in Clinic)
Development of Staccato Prochlorperazine for the treatment of migraine headache.
- Trial name
- NCT00610428
- Testing
- Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraines
Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)
The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura.
- Trial name
- NCT00483704
- Testing
- Telcagepant 140 mg, Talcagepant 280 mg
- Volunteers
- 1,935 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine, Chronic Migraine, Headache
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with…
- Conditions
- Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
- Trial name
- PREVENTION (NCT05679908)
- Testing
- TNX-1900
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03777059
- Testing
- Atogepant
- Where
- 138 sites in United States
- Volunteers
- 910 people
- Sponsor
- Allergan
Migraine, Migraine With Aura
A Study of a Melatonin Receptor Agonist to Prevent Migraine
The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT00739024
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Swedish Medical Center
Migraine, Migraine With Aura
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- ASCEND (NCT04406649)
- Testing
- Dihydroergotamine
- Where
- 44 sites in United States
- Volunteers
- 482 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine With Aura
Study of NXN 188 for the Treatment of Migraine With Aura
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
- Trial name
- NCT00920686
- Testing
- NXN-188, sumatriptan succinate
- Where
- 16 sites in United States
- Volunteers
- 239 people
- Sponsor
- NeurAxon Inc.
Migraine
A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine
This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.
- Trial name
- MONONOFU (NCT03962738)
- Testing
- Lasmiditan
- Where
- 34 sites in Japan
- Volunteers
- 846 people
- Sponsor
- Eli Lilly and Company